As of July 26, 2026, 21 CFR 216.23 lists six substances that can be used through this pathway: Brilliant Blue G, cantharidin for topical use only, diphenylcyclopropenone for topical use only, N-acetyl-D-glucosamine for topical use only, squaric acid dibutyl ester for topical use only, and thymol iodide for topical use only
doi: 10.1517/13543784.2011.630660 13 GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art - PubMed
Semaglutide or GLP-1 receptor agonists should be the preference, as the data does not support lipotropic injections for significant weight loss, Dr
2.2 Treatment and tolerance tests Male and female mice (22- to 25-week-old) were placed in clean cages and food withheld for five hours
This difference directly translates to lower deviation rates and reduced rework costs in commercial production
There were no follow-up questions about my unrealistic weight-loss goal, no request for medical records and no request for lab work